221 West Philadelphia Street
York, Pennsylvania 28277-3607
Dentsply Sirona remains fundamentally stable and has a growing dividend with a strong buyback catalyst. Click here to see why XRAY stock is a Buy.
Dentsply Sirona (XRAY) plans to repurchase $150M of its common stock through an accelerated share repurchase agreement with Goldman Sachs.The agreement will be completed under…
CHARLOTTE, N.C., March 06, 2023 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced that it has entered into an accelerated share repurchase agreement (the “ASR”) with Goldman Sachs & Co. LLC to repurchase $150 million of its common stock. The ASR agreement will be completed under Dentsply Sirona’s current share repurchase authorization.
FY22 net sales decreased (7.3%) to $3,922 million , organic sales decreased (0.5%) FY22 GAAP EPS of ( $4.41 ) , adjusted EPS of $2.09 Q4 net sales decreased (10.9%) to $983 million , organic sales decreased (2.6%) Q4 GAAP EPS of ( $0.07 ), adjusted EPS of $0.46 FY23 outlook: net sales of
Dentsply Sirona (XRAY) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open.The consensus EPS Estimate is $0.33 (-56.6% Y/Y) and the consensus…
Dentsply Sirona (NASDAQ: XRAY ) is set to give its latest quarterly earnings report on Tuesday, 2023-02-28. Here''s what investors need to know before the announcement. Analysts estimate that Dentsply Sirona will report an earnings per share (EPS) of $0.32. Dentsply Sirona bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Dentsply Sirona Inc (NASDAQ: XRAY ) announced an organizational restructuring plan and anticipates achieving at least $200 million in annual cost savings over the next 18 months . The restructuring plan consists of a reduction in the global workforce of approximately 8% - 10%. The company will also … Full story available on Benzinga.com
Dentsply Sirona (XRAY) will undergo a organization restructuring that will save an anticipated $200M-$225M annually in cost savings.
Dentsply Sirona manufactures and sells various dental products and technologies for professional dental market worldwide. Read my analysis of XRAY stock.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has a beta value of 0.94 and has seen 0.96 million shares traded in the recent trading session. The company, currently valued at $7.87B, closed the recent trade at $36.51 per share which meant it gained $0.62 on the day or 1.73% during that session. The XRAY stock price is -60.78% … DENTSPLY SIRONA Inc. (XRAY) Has Great Growth Outlook For 2023 Read More »
The Dental Treatment Consumables and Equipment Market outlook looks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data. The
Major players in the dental implants market are Zimmer Biomet Holdings Inc., OSSTEM IMPLANT, Institut Straumann AG, Bicon LLC, DENTSPLY Sirona, Danaher Corporation, BioHorizons IPH Inc, Shofu Dental Corporation, Thommen Medical AG, and Ivoclar Vivadent Inc. Major players in the dental implants market are Zimmer Biomet Holdings Inc., OSSTEM IMPLANT, Institut Straumann AG, Bicon LLC, DENTSPLY Sirona, Danaher Corporation, BioHorizons IPH Inc, Shofu Dental Corporation, Thommen Medical AG, and Ivoclar Vivadent Inc.
CHARLOTTE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Tuesday, February 28, 2023, at 8:30 am ET to review its fourth quarter and full year 2022 financial results. A presentation related to the call will be available on the Investors section of the Company’s website at https://investor.dentsplysirona.com.